[go: up one dir, main page]

MX2010013760A - Preparacion de formas farmaceuticas relajantes de musculos esqueleticos de liberacion controlada. - Google Patents

Preparacion de formas farmaceuticas relajantes de musculos esqueleticos de liberacion controlada.

Info

Publication number
MX2010013760A
MX2010013760A MX2010013760A MX2010013760A MX2010013760A MX 2010013760 A MX2010013760 A MX 2010013760A MX 2010013760 A MX2010013760 A MX 2010013760A MX 2010013760 A MX2010013760 A MX 2010013760A MX 2010013760 A MX2010013760 A MX 2010013760A
Authority
MX
Mexico
Prior art keywords
preparation
dosage forms
controlled release
skeletal muscle
muscle relaxant
Prior art date
Application number
MX2010013760A
Other languages
English (en)
Inventor
Venkatesh Gopi
m clevenger James
Grinstead Timothy
Original Assignee
Eurand Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41434443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010013760(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand Inc Star filed Critical Eurand Inc Star
Publication of MX2010013760A publication Critical patent/MX2010013760A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método para preparar una composición farmacéutica de liberación prolongada que comprende ciclobenzaprina, que comprende recubrir partículas inertes con una composición estratificante de fármaco que contiene ciclobenzaprina para formar microesferas LI, posteriormente recubrir las microesferas LI con un recubrimiento de liberación prolongada para formar microesferas LP.
MX2010013760A 2008-06-20 2009-06-18 Preparacion de formas farmaceuticas relajantes de musculos esqueleticos de liberacion controlada. MX2010013760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7446408P 2008-06-20 2008-06-20
PCT/US2009/047807 WO2009155426A1 (en) 2008-06-20 2009-06-18 Preparation of controlled release skeletal muscle relaxant dosage forms

Publications (1)

Publication Number Publication Date
MX2010013760A true MX2010013760A (es) 2011-03-29

Family

ID=41434443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010013760A MX2010013760A (es) 2008-06-20 2009-06-18 Preparacion de formas farmaceuticas relajantes de musculos esqueleticos de liberacion controlada.

Country Status (28)

Country Link
US (3) US20090148532A1 (es)
EP (1) EP2303020B1 (es)
JP (1) JP5636364B2 (es)
KR (1) KR101451823B1 (es)
CN (2) CN102065691A (es)
AR (2) AR072267A1 (es)
AU (1) AU2009259993B2 (es)
BR (1) BRPI0914225B1 (es)
CA (1) CA2727935C (es)
CL (1) CL2009001447A1 (es)
CO (1) CO6300903A2 (es)
CR (1) CR11864A (es)
CY (1) CY1118878T1 (es)
DK (1) DK2303020T3 (es)
ES (1) ES2625485T3 (es)
HU (1) HUE032182T2 (es)
IL (1) IL209997A0 (es)
MX (1) MX2010013760A (es)
MY (2) MY153712A (es)
NZ (1) NZ589856A (es)
PL (1) PL2303020T3 (es)
PT (1) PT2303020T (es)
RU (1) RU2540494C2 (es)
SG (1) SG193816A1 (es)
TW (2) TW201503915A (es)
UY (1) UY31928A (es)
WO (1) WO2009155426A1 (es)
ZA (2) ZA201009083B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
WO2010133961A1 (en) * 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
EP2501234B1 (en) * 2009-11-20 2017-09-13 Tonix Pharma Holdings Limited Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
WO2013158638A1 (en) * 2012-04-17 2013-10-24 Mylan, Inc. Stable dosage forms of skeletal muscle relaxants with extended release coating
AU2013274003B2 (en) * 2012-06-15 2018-07-05 Tonix Pharma Limited Compositions and methods for transmucosal absorption
MX370021B (es) 2013-03-15 2019-11-28 Tonix Pharmaceuticals Inc Formulaciones eutécticas de clorhidrato de ciclobenzaprina y de clorhidrato de amitriptilina.
WO2016044796A1 (en) 2014-09-18 2016-03-24 Seth Lederman Eutectic formulations of cyclobenzaprine hydrochloride
EA201992116A1 (ru) * 2017-03-08 2020-01-29 СИНРКС ФАРМА, ЭлЭлСи Фармацевтические составы флороглюцинола и триметилфлороглюцинола
BR112020011345A2 (pt) 2017-12-11 2020-11-17 Tonix Pharma Holdings Limited tratamento com ciclobenzaprina para agitação, psicose e declínio cognitivo na demência e condições neurodegenerativas
CN109381446A (zh) * 2018-11-26 2019-02-26 正大制药（青岛）有限公司 一种盐酸环苯扎林缓释胶囊
CN111374942B (zh) * 2018-12-30 2022-09-13 鲁南制药集团股份有限公司 一种甾体类肌松药注射液及其制备方法
CN114432266B (zh) * 2021-12-23 2023-03-10 南通联亚药业股份有限公司 一种稳定的盐酸环苯扎林缓释胶囊

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882246A (en) 1971-05-21 1975-05-06 Merck & Co Inc Treatment of skeletal muscle disorders with cyclobenzaprine
US4337582A (en) * 1980-09-30 1982-07-06 Airco, Inc. Methods for controlling vapor concentrations in an atmosphere
US4685918A (en) 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US5047258A (en) 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
WO2001019901A2 (en) * 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
US6576702B2 (en) 2000-07-20 2003-06-10 Noveon Ip Holdings Corp. Plasticized waterborne polyurethane dispersions and manufacturing process
AU2003224794A1 (en) 2002-03-29 2003-10-13 Alza Corporation Volume efficient controlled release dosage form
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
US20050158383A1 (en) 2003-10-21 2005-07-21 Garth Boehm Quetiapine formulations
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20060039975A1 (en) 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
US20060263429A1 (en) * 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
WO2007110875A1 (en) * 2006-03-24 2007-10-04 Panacea Biotec Ltd. Antibiotic compositions of modified release and process of production thereof
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms

Also Published As

Publication number Publication date
CN106860430A (zh) 2017-06-20
EP2303020B1 (en) 2017-02-22
ES2625485T3 (es) 2017-07-19
KR101451823B1 (ko) 2014-10-16
UY31928A (es) 2010-01-29
US20120196028A1 (en) 2012-08-02
EP2303020A1 (en) 2011-04-06
US8137734B2 (en) 2012-03-20
BRPI0914225A8 (pt) 2018-02-06
TW201004615A (en) 2010-02-01
WO2009155426A1 (en) 2009-12-23
ZA201109534B (en) 2013-10-30
BRPI0914225A2 (pt) 2017-11-07
CO6300903A2 (es) 2011-07-21
US20100098832A1 (en) 2010-04-22
TWI458480B (zh) 2014-11-01
IL209997A0 (en) 2011-02-28
PL2303020T3 (pl) 2017-08-31
JP5636364B2 (ja) 2014-12-03
RU2540494C2 (ru) 2015-02-10
SG193816A1 (en) 2013-10-30
EP2303020A4 (en) 2013-12-04
RU2011101918A (ru) 2012-07-27
DK2303020T3 (en) 2017-05-01
JP2011525188A (ja) 2011-09-15
PT2303020T (pt) 2017-06-02
CA2727935A1 (en) 2009-12-23
NZ589856A (en) 2012-06-29
CN102065691A (zh) 2011-05-18
AR113877A2 (es) 2020-06-24
CA2727935C (en) 2017-05-30
MY153712A (en) 2015-03-13
CL2009001447A1 (es) 2009-08-21
MY173408A (en) 2020-01-22
CY1118878T1 (el) 2018-01-10
BRPI0914225B1 (pt) 2021-08-31
KR20110025654A (ko) 2011-03-10
HUE032182T2 (en) 2017-09-28
CR11864A (es) 2011-05-16
US20090148532A1 (en) 2009-06-11
ZA201009083B (en) 2012-03-28
AU2009259993B2 (en) 2013-10-31
TW201503915A (zh) 2015-02-01
AR072267A1 (es) 2010-08-18
AU2009259993A1 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
MY153712A (en) Preparation of controlled release skeletal muscle relaxant dosage forms
SI2273983T1 (sl) Postopek za pripravo intermediatne praškaste formulacije in končne trdne odmerne oblike z uporabo stopnje strjevanja z razprševanjem
NZ589437A (en) Immediate release tablet comprising 5-azacytidine and a non-enteric coating applied with an ethanol solvent
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
PH12015500460B1 (en) Coated pharmaceutical composition containing regorafenib
MX2014004196A (es) Citramida de rasagilina.
ZA202210822B (en) Preparation of solid dosage forms comprising antibodies by solution/suspension layering
MY179886A (en) Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs
IN2014DN03429A (es)
WO2012002773A3 (en) Phenylcarbamate compound and muscle relaxant containing the same
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
IL209944A (en) Phenyl-Alkyl Paprazine Compounds, Process for Preparation, Pharmaceutical Composition and Drug Containing them
WO2013124832A3 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
SA112330438B1 (ar) تركيبة صيدلانية محتوية على محصر للعصب العضلي أو عامل ارتخاء للعضل الهيكلي وطريقة تحضيرها
UA56367U (en) composition neuroactive preparation
GB201109231D0 (en) Pharmaceutical composition comprising bosentan
SI2471513T1 (sl) Postopek za pripravo zdravilne učinkone (API) v obliki pelet
UA102549C2 (ru) Способ получения уплотненного промежуточного продукта дималеата bibw 2992, уплотненный промежуточный продукт и твердая пероральная таблетка
HK1150552A (en) Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
PL397563A1 (pl) Postac farmaceutyczna zawierajaca terapeutycznie skuteczna ilosc antagonisty receptorów AT1 angiotensyny II - losartanu potasu oraz sposób jej wytwarzania

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration